AxoGen (AXGN) Q2 2024 earnings summary

Executive summary

• Q2 2024 revenue grew 25.6% year-over-year to $47.9 million, driven by commercial execution, increased sales rep productivity, and favorable product mix.

• Net loss narrowed to $1.9 million ($0.04/share) from $6.7 million ($0.16/share) in Q2 2023; adjusted net income was $2.0 million ($0.05/share).

• Adjusted EBITDA reached $5.6 million, a significant improvement from a loss last year.

• Core accounts (>$100K TTM revenue) increased to 412, representing 65% of total revenue.

• Full launch of Avive+ Soft Tissue Matrix completed in June 2024, with positive early feedback and continued adoption.

Financial highlights

• Q2 2024 revenue: $47.9 million (+25.6% YoY); gross profit: $35.3 million (up from $29.7 million); gross margin: 73.8% (down from 77.7%).

• Operating expenses decreased 2.1% to $35.8 million, mainly due to lower R&D and royalty fees.

• Net loss for Q2 2024 was $1.9 million, improved from $6.7 million loss YoY; adjusted net income was $2.0 million.

• Cash, cash equivalents, and investments totaled $27.1 million at June 30, 2024, up from $23.6 million at March 31, 2024.

• $50 million outstanding under credit facility, with maturities in 2027 and 2028; interest rate at 12.90%.

Outlook and guidance

• Full-year 2024 revenue guidance raised to $182–186 million; gross margin expected between 74% and 76%.

• Expects to be net cash flow positive cumulatively from April 1 through year-end 2024.

• Management expects to complete the rolling BLA submission for Avance Nerve Graft in Q3 2024, targeting potential FDA approval in mid-2025.